Ex vivo functional diagnostics of fresh, uncultured GBM biopsies with AMG232 and irradiation

Here, we first measured expression changes of therapy-related and GBM-specific markers between control and treated (AMG232 and radiotherapy) samples. Then, we applied a predictive algorithm, which used these expression changes to estimate cellular survival. The predictive model was previously generated and trained on patient-derived GBM cell lines with heterogeneous genetic background and variable sensitivity profiles demonstrated upon AMG232 and radiotherapy exposure.
Conclusion:
With this trial, we concluded that in vitro treatment of freshly resected and dissociated GBM samples is feasible and provides insights towards treatment sensitivity of phenotypically distinct tumour populations. Mass cytometry screening